It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mesenchymal cells expressing platelet-derived growth factor receptor beta (PDGFRβ) are known to be important in fibrosis of organs such as the liver and kidney. Here we show that PDGFRβ+ cells contribute to skeletal muscle and cardiac fibrosis via a mechanism that depends on αv integrins. Mice in which αv integrin is depleted in PDGFRβ+ cells are protected from cardiotoxin and laceration-induced skeletal muscle fibrosis and angiotensin II-induced cardiac fibrosis. In addition, a small-molecule inhibitor of αv integrins attenuates fibrosis, even when pre-established, in both skeletal and cardiac muscle, and improves skeletal muscle function. αv integrin blockade also reduces TGFβ activation in primary human skeletal muscle and cardiac PDGFRβ+ cells, suggesting that αv integrin inhibitors may be effective for the treatment and prevention of a broad range of muscle fibroses.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Department of Trauma and Orthopaedics, University of Edinburgh, Edinburgh, UK; BHF Centre for Vascular Regeneration & MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
2 BHF Centre for Vascular Regeneration & MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK
3 MRC Centre for Inflammation Research, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK
4 Department of Trauma and Orthopaedics, University of Edinburgh, Edinburgh, UK
5 Center for World Health and Medicine, Saint Louis University, Edward A. Doisy Research Center, St. Louis, USA
6 BHF Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, UK
7 Department of Pediatric Surgery, University of Texas McGovern Medical School, TX, USA; Center for Stem Cell and Regenerative Medicine, The Brown Foundation Institute of Molecular Medicine (IMM), The University of Texas Health Science Center at Houston (UT Health), TX, USA
8 University of Bristol, Bristol, UK
9 Steadman Philippon Research Institute, Vail, USA; Department of Orthopaedic Surgery, University of Texas, Medical School at Houston, Houston, USA
10 BHF Centre for Vascular Regeneration & MRC Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK; Orthopaedic Hospital Research Center and Broad Stem Cell Research Center, University of California, Los Angeles, USA